1	Decoding mitochondrial genes in pediatric AML and development of a
2	novel prognostic mitochondrial gene signature
3	Shilpi Chaudhary ¹ , Shuvadeep Ganguly ¹ , Jayanth Kumar Palanichamy ² , Archna Singh ² ,
4	Dibyabhaba Pradhan ³ , Radhika Bakhshi ⁴ , Anita Chopra ⁵ , Sameer Bakhshi ¹
5	¹ Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
6	² Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India
7	³ ICMR Computational Genomics Centre, Indian Council of Medical Research, New Delhi,
8	India
9	⁴ Shaheed Rajguru College of Applied Sciences for Women, University of Delhi, Delhi, India
10	⁵ Department of Laboratory Oncology, All India Institute of Medical Sciences, New Delhi,
11	India.
12	
13	Corresponding author:
14	Prof. Sameer Bakhshi
15	Department of Medical Oncology
16	Dr. B.R.A. Institute Rotary Cancer Hospital
17	All India Institute of Medical Sciences,
18	New Delhi – 110029, INDIA
19	Email: sambakh@hotmail.com
20	Office Phone Number: +91-11-29575237
21	Fax Number: +91-11-26588153
22	
23	Abstract Word Count: 250
24	Text Word Count: 5063
25	No. of Tables: 8
26	No. of Figures: 12
27	Supplementary files: 1 (Supplementary Tables: 6)
28	No. of References: 52
29	Running title: Mitochondria-related prognostic gene signature in AML

31 Abstract

32 Background

Gene expression profile of mitochondrial-related genes is not well deciphered in pediatric
acute myeloid leukaemia (AML). We aimed to identify mitochondria-related differentially
expressed genes (DEGs) in pediatric AML with their prognostic significance.

36 Methods

37 Children with *de novo* AML were included prospectively between July 2016-December 2019.
38 Transcriptomic profiling was done for a subset of samples, stratified by mtDNA copy
39 number. Top mitochondria-related DEGs were identified and validated by real-time PCR. A
40 prognostic gene signature risk score was formulated using DEGs independently predictive of
41 overall survival (OS) in multivariable analysis. Predictive ability of the risk score was
42 estimated along with external validation in The Tumor Genome Atlas (TCGA) AML dataset.

43 **Results**

In 143 children with AML, twenty mitochondria-related DEGs were selected for validation, 44 of which 16 were found to be significantly dysregulated. Upregulation of SDHC (p<0.001), 45 CLIC1 (p=0.013) and downregulation of SLC25A29 (p<0.001) were independently predictive 46 of inferior OS, and included for developing prognostic risk score. The risk score model was 47 48 independently predictive of survival over and above ELN risk categorization (Harrell's cindex: 0.675). High-risk patients (risk score above median) had significantly inferior OS 49 (p<0.001) and event free survival (p<0.001); they were associated with poor-risk cytogenetics 50 51 (p=0.021), ELN intermediate/poor risk group (p=0.016), absence of RUNX1-RUNX1T1

- 52 (p=0.027), and not attaining remission (p=0.016). On external validation, the risk score also
- 53 predicted OS (p=0.019) in TCGA dataset.

Conclusion 54

- We identified and validated mitochondria-related DEGs with prognostic impact in pediatric 55
- AML and also developed a novel 3-gene based externally validated gene signature predictive 56
- of survival. 57

58	Keywords: Acute Myeloid Leukaemia, Mitochondria, Gene signature, RNA sequencing,
59	Child
60	
61	
62	
63	
64	
65	
66	
67	
69	
70	
71	
, 1	

72 Introduction

Despite recent advancements, the survival in pediatric acute myeloid leukaemia (AML) continues to remain dismal(1). Various molecular and genetic alterations are frequently used for risk stratification, identification of therapeutic targets as well as predicting disease prognosis in AML(2). Whole genome and transcriptome sequencing have been extensively used in AML to identify potential novel molecular targets and developing prognostic gene signatures to predict survival, relapse and risk stratification(3–5). However, data on potential mitochondrial genes with impact on AML are limited.

Dysregulation of mitochondrial pathways have been implicated in pathogenesis and 80 progression of various malignancies(6). Multiple studies have reported the role of 81 82 mitochondrial DNA (mtDNA) mutations, metabolic pathways and oxidative phosphorylation, 83 on disease biology and prognosis of AML(7,8). We have previously reported the relationship of mutations in mtDNA regulatory region with mitochondrial gene expression, and their 84 85 impact on survival in children with AML(9-11). Considering the impact of mitochondrial pathways in outcome of AML, it is important to explore tumor cell heterogeneity in AML 86 with respect to mitochondrial transcriptome and identify potential therapeutic or prognostic 87 molecular targets. 88

Recently, we have reported that high mtDNA copy number is associated with poor outcome in paediatric AML and also identified its potential regulation through *PGC1A*(12). In the current study, among children with AML stratified according to mtDNA copy number, we identified mitochondria-related differentially expressed genes (DEGs) through whole transcriptome sequencing. We further validated the topmost identified mitochondria-related DEGs in a cohort of paediatric AML patients and formulated a prognostic mitochondrial gene signature for predicting survival outcome. We then validated this gene signature in an

96	external cohort of adult AML	patients from	The Cancer	Genome Atlas	(TCGA)	dataset along
		1			· /	0

97 with estimation of predictive ability of the developed prognostic gene signature.

98 Methodology

99 Study design, patient population, treatment and clinical follow up

This was a prospective observational cohort study that included consecutive de novo 100 paediatric (≤ 18 years) patients with AML registered from July 2016 to December 2019 at 101 medical oncology outpatient clinic of our cancer centre. The workflow of the study is 102 103 depicted in figure 1. Study was ethically approved by institute ethics committee (IEC/NP-336/2012, IECPG-79/22.03.2017) and informed consent was taken from care givers and 104 assent was obtained from all participants (≥ 8 years). Patients with granulocytic sarcoma 105 106 without marrow involvement, acute promyelocytic leukaemia, and mixed phenotypic acute leukaemia were excluded. Fifty age-matched patients of solid malignancies without marrow 107 involvement were also enrolled as controls. Remission status and survival outcomes were 108 noted. 109

110 Risk Assessment by karyotyping and mutation analysis

111 Conventional cytogenetics were done at baseline to identify translocations, inversions, 112 deletion as well as other chromosomal abnormalities for risk stratification of pediatric AML. Mutation profiling of *RUNX1-RUNX1T1* (Runt-related transcription factor 1-RUNX1 partner 113 transcriptional co-repressor 1 fusion transcript), CBFB-MYH11 (Core binding factor beta-114 115 myosin heavy chain 11 fusion transcript), FLT3-ITD (Fms like tyrosine kinase 3-internal tandem duplication), and NPM1 (Nucleophosmin 1) by reverse transcriptase polymerase 116 chain reaction (PCR) were performed at baseline for risk assessment as per European 117 LeukemiaNet (ELN) recommendation (13). 118

119 Treatment protocol

All patients were treated with uniform induction protocol, i.e., 3+7 regimen including 120 daunorubicin 60 mg/m² day 1-3 and cytarabine 100mg/m² continuous infusion day 1-7. 121 Consolidation therapy with three cycles of high dose cytarabine at $18g/m^2$ were given to 122 patients after achieving complete remission (CR) whereas repeated induction with ADE 123 regimen (cytarabine: 100 mg/m2 twice daily, day 1-10; daunorubicin: 50 mg/m2, day 1-3; 124 and etoposide: 100 mg/m2, day 1-5) were used for refractory or relapse cases. Patients at 125 CR2 underwent allogeneic hematopoietic stem cell transplantation with matched sibling 126 donor if available (13,14). 127

128 Isolation of bone marrow mononuclear cells (BMMCs), DNA and RNA extraction and

129 quantification

BMMCs were isolated by Ficoll-Hypaque (Sigma diagnostics, USA) density gradient 130 131 centrifugation followed by isolation of total RNA and DNA. Briefly, BM samples collected from all the patients and controls were layered onto the histopaque in 15 ml falcon tube 132 followed by centrifugation at 400g for 30 min at room temperature. The mononuclear cells 133 layer was carefully taken out after centrifugation and washed twice with phosphate buffer 134 saline (PBS). BMMC were then stored for DNA isolation using isopropanol precipitation 135 method and total RNA was isolated using TRIzol method as per manufacturer's protocols. 136 Quality of DNA and RNA was checked by Nanodrop 1000 (Thermo Fisher) and integrity of 137 RNA was checked by TapeStation (Agilent). 138

139 Estimation of mitochondrial DNA copy number

Relative mtDNA copy number was assessed by fluorescent DNA binding dye SYBR based
quantitative real time PCR using, with Roche Light Cycler 480 II. The relative mitochondrial
DNA copy number was normalized to expression of nuclear gene *ACTB*, which was chosen
as a nuclear housekeeping gene. The mitochondrial DNA copy number, normalized to copies

144 per cell, in each subject and control sample was calculated using the following formula: 145 $2^{Ct}(\beta - \arctan) - Ct \text{ (minor arc)]}$ (Ct being respective cycle thresholds). Relative 146 mitochondrial DNA copy numbers of patients were then compared with controls.

147 Whole transcriptome sequencing, identification of differentially expressed genes (DEG)

148 and selection of DEG for analysis

149 All the samples were classified into three separate groups based on relative mtDNA copy number(12). Patients were categorized into: AMLCN H (mtDNA copy number $> 75^{\text{th}}$ 150 151 percentile), AMLCN_I (mtDNA copy number 50th to 75th percentile) and AMLCN_L (mtDNA copy number < 50th percentile) groups. A subset of samples was randomly selected 152 153 from each of the three sub-groups and controls with RNA integrity score above 7 and a total of 15 samples (12 patients including 3 from AMLCN H group, 4 from AMLCN I group, 5 154 from AMLCN L group and 3 controls) were sent for whole transcriptome profiling for the 155 identification of DEGs compared to controls. 156

157 Library Construction and sequencing

The sequencing library was prepared by random fragmentation of the cDNA sample, 158 followed by 5' and 3' adapter ligation, after end-repair and the addition of an 'A' base and 159 SPRI clean-up. The prepared cDNA library was amplified using PCR for the enrichment of 160 the adapter-ligated fragments. The individual libraries were quantified using a NanoDrop 161 spectrophotometer (Thermo Scientific) and validated for quality with a Bioanalyzer (Agilent 162 Technologies). Adapter-ligated fragments were then PCR amplified and gel purified. cDNA 163 library was used for sequencing which was carried out on Illumina Hiseq 4000 NGS 164 platform. 165

166 **Processing of the reads and differential expression analysis**

The quality of raw reads was first checked by FastQC version v0.11.8. Trimmomatic was 167 performed to remove adapter sequences and low-quality reads for further analysis. The 168 trimmed reads were then aligned to reference Human genome (hg38) using HISAT2 tool. 169 SAM tool was used to convert SAM files into BAM files which was used for quantification 170 and estimation of aligned reads by StringTie (v2.0.6). Lastly differential expression analysis 171 was performed by limma Bioconductor package (version 3.48.1). Absolute fold change value 172 ≥ 2 (a \geq two-fold change in expression, either upregulated or downregulated) and adjusted p 173 value ($q \le 0.05$) threshold was used for the identification of differentially expressed genes 174 175 (DEGs). Volcano plots were made with log fold change; p value and adjusted p value of the transcripts were calculated using devtools in R package (version 3.6.1). Gene name of the 176 corresponding transcripts with significant p value, adjusted p value and log 2-fold difference 177 compared to controls, were fetched using gProfilerR library in R package. Exclusive 178 differentially expressed genes were identified among the groups by making Venn diagram 179 using Venny (Venny 2.1) online tool. (Figure 2). 180

181 Construction of protein-protein interaction network, determination of HUB genes and 182 MCODE analysis

183 A interactive network of proteins encoded DEGs present in the respective groups were constructed using Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) 184 185 database (15) in Cytoscape. Cytohubba plugin was used for identifying Hub genes among the whole interactome network. Those genes which got enriched using at least six different 186 topological algorithms among Degree, Edge Percolated Component (EPC), Maximum 187 Neighbourhood Component (MNC), Density of Maximum Neighbourhood Component 188 (DMNC), Maximal Clique Centrality (MCC) and centralities based on shortest paths, such as 189 Bottleneck (BN), Eccentricity, Closeness, Radiality, Betweenness, and Stress were 190 considered as Hub genes(16). Cytoscape plug-in MCODE clustering algorithm was used for 191

identifying the maximum ranked cluster which has a highly interconnected region, also
known as seed nodes as well as their neighbour nodes in the whole network (17). Subcellular
location of the genes was identified from the gene ontology table. Compartment mitochondria
score was used for selecting mitochondrial related genes among all the AML subgroups.

196 Selection and validation of mitochondria-related DEGs

Out of all identified DEGs from transcriptome sequencing, mitochondria-related genes were 197 filtered using Cytoscape compartment mitochondrion score (0 being minimum and 5 being 198 199 highest)(18). DEGs with topmost mitochondrial compartment score were selected for validation in a cohort of paediatric patients with AML. The genes of MCODE cluster 1 and 200 Hub genes were assessed for their mitochondrial localization as above and genes in each 201 202 group with highest mitochondrial compartment score were selected for validation. Based on 203 these selection strategies, a total of 20 mitochondria-related DEGs were selected for validation. Real time PCR was performed to validate the selected mitochondria-related genes 204 205 using specific primers (Table S1) and the gene expressions were quantified per previously described protocol(12). All experiments were replicated in triplicates. 206

207 Comparison of validated mitochondria-related DEGs in TCGA data set

For external validation of mitochondrial related DEGs, the RNA-sequencing data (Illumina 208 HiSeq 2000) of TCGA adult AML(LAML) dataset was chosen, which is one of the largest 209 210 datasets of transcriptomic profile in AML with recorded clinical outcome(<u>https://www.cbioportal.org/ study/summary? id=laml_tcga</u>). The adult dataset was 211 specifically chosen to see the impact of prognostic impact of the validated mitochondria-212 related age group in a different age group as well. The expression of validated DEGs was 213 compared with LAML data set using online available GEPIA2 (Gene Expression Profiling 214 215 Interactive Analysis) web server (http://gepia2.cancer-pku.cn/#index)(19).

216 Statistical Methods

Prognostic impact of mitochondria-related DEGs and development of mitochondrial gene signature

Statistical analysis was carried out in SPSS (v23, IBM, NY, USA). Descriptive statistics were 219 used to summarize baseline characteristics. Gene expression was reported as median values 220 with interquartile ranges. Gene expression values and clinical continuous variables with non-221 222 parametric distribution were compared by Mann Whitney test. Clinical categorical variables were compared by Chi-square test/Fisher's exact test as applicable. Alpha error was adjusted 223 224 for multiple comparisons by Bonferroni correction. Kaplan Meier method was used to analyse time to event outcomes. Duration from enrolment to relapse or death due to any cause 225 was considered as event free survival (EFS). Time from enrolment to death due to any cause 226 was defined as overall survival (OS). Survival data was censored till 31st Dec 2020. The 227 follow-up estimation was done by reverse Kaplan Meier method. 228

Prognostic impact of all validated DEGs on OS of the whole validation cohort was performed 229 230 by multivariable Cox regression analysis in a forward stepwise manner based on log likelihood change. Validated DEGs with significant (p<0.05) predictive impact on OS in 231 multivariable analysis were included for the prognostic gene signature model. The 232 proportional hazard assumption was assessed by Schoenfeld global test. Internal validation of 233 the multivariable prognostic model was carried out by bootstrapping method (10000 234 235 resampling) and genes that did not satisfy bootstrapping validation were excluded. A prognostic risk score was generated using cox regression coefficient Beta (β) values of 236 included genes, of the final multivariable model as below: 237

Risk score =
$$\left[\sum_{k=0}^{n} {n \choose k} \{ \beta_k \times (Expression \ mRNA_k) \} \right] \times 100$$

The area under the time-dependent receiver operating characteristic (ROC) curve (Timed AUC) for 12-months and 18-months survival was estimated and Harrel's C-index of the prognostic model was calculated using the R package "survminor" in R (version 4.0.3). Patients were classified into two groups based on their risk score above (High-risk) and below (Low-risk) the median. The survival outcomes of the patients were compared between high-risk score vs low-risk score patients using Kaplan Meier analysis to evaluate the prognostic significance of the gene signature model.

245 Impact of clinical features and independent prognostic value of the gene signature

246 The role of demographic and clinical features, including gender, age, haemoglobin, hyperleukocytosis (≥50000/µl), platelet count, presence of chloroma and ELN risk 247 stratification(2)on survival outcome was analysed using the Cox regression. Factors with 248 249 p<0.1 in univariable analysis were included for multivariable Cox regression in a forward 250 stepwise manner using log likelihood change. Clinico-demographic factors which were significant in multivariable analysis were included in a multivariable Cox regression model 251 along with gene signature risk score to explore the independent predictive value of gene 252 signature. The timed AUC using 12-months survival and 18-months survival as the outcome 253 and Harrel's C-index of the clinical prognostic model and combined clinical and gene 254 signature prognostic model were compared for identifying the additional prognostic benefits 255 of gene signature over clinical parameters. The impact of mtDNA copy number on survival 256 257 outcome was also analysed similarly.

258 External validation of mitochondrial prognostic gene signature in TCGA dataset

The prognostic impact of our gene signature risk score on OS was done in TCGA LAML (n=179) dataset by Cox regression analysis. Patients were similarly sub-grouped into highrisk and low-risk category based on median value of the gene signature; the survival outcomes of the patients were compared between high-risk score vs low-risk score patients using Kaplan Meier analysis and timed AUC of 12-month and 18-month survival was evaluated. Based on available karyotyping data, patients of the TCGA dataset were grouped into poor-risk karyotype and others (including good and intermediate-risk karyotype). The karyotype category and mitochondrial gene risk score were assessed for their impact on OS by a multivariable Cox regression model to explore the independent predictive value of the gene signature in the external cohort as well.

269 **Results**

270 Patients' recruitment and baseline clinical features

Total 170 patients were enrolled, out of which 27 patients (5 patients were AML M3, 4 had 271 granulocytic sarcoma without marrow involvement, and 18 patients had insufficient samples) 272 were excluded. The baseline demographic and clinical characteristics of final 143 patients are 273 summarized in Table 1. Median age was 10 years (range: 0.8-18 years) and 50% of the 274 patients were classified as ELN good risk. Total 104 patients (72.7%) achieved complete 275 remission (CR) after induction therapy. At median follow-up of 36 months (32.67-39.33 276 months), the median OS was 21.93 months (13.54–30.31 months). The clinical characteristics 277 of the TCGA LAML dataset are summarized in Table S2. 278

279 Identification of DEGs in paediatric AML based on mtDNA copy number

We identified 898,769, and 953 significantly dysregulated transcripts in AMLCN H, 280 AMLCN I and AMLCN L groups respectively by whole transcriptome sequencing as 281 represented in volcano plots (Figure 3). Majority of genes were found significantly 282 downregulated in all three groups whereas the number of dysregulated genes were higher in 283 AMLCN H group compared to other two groups. A total of 351 DEGs (59 upregulated and 284 292 downregulated) were identified in AMLCN_H. Similarly, AMLCN_I and AMLCN_L 285 groups had 290 (66 upregulated and 224 downregulated) and 332 (47 upregulated and 285 286 downregulated) DEGs respectively as compared to controls. 287

Identification of mitochondria-related DEGs, hub genes and selection of genes for validation

Out of all DEGs, 78, 58, and 71 mitochondria-related DEGs were identified in AMLCN H, 290 AMLCN I and AMLCN L groups respectively. Among them, 35 genes were common in all 291 three subgroups, whereas 18, 12 and 14 mitochondria-related DEGs were exclusively present 292 293 in AMLCN_H, AMLCN_I and AMLCN_L groups respectively (Figure 4). In AMLCN_H, AMLCN_I and AMLCN_L groups, we identified 17, 18 and 17 hub genes respectively using 294 CytoHubba analysis, of which eight were common among all subgroups (Table S3, Figure 5). 295 Furthermore, using MCODE analysis, clusters with maximum scores were generated and 296 seed gene was determined in the three groups (Figure 6). MMP9 was identified as seed node 297 with maximum MCODE score in both AMLCN_H and AMLCN_I group (Table S4). Based 298 on the mitochondrial compartment score, CytoHubba and MCODE analyses, a total of 20 299 DEGs were selected for further validation (Table 2). 300

301 Validation of selected DEGs, comparison with TCGA database

In the validation cohort of 143 AML patients, the expression of SLC25A3, SDHC, 302 RACK1/GNB2L1, FASTKD1, ATP5J, CLIC1, GLUD1, and SLC25A29 were found to be 303 significantly upregulated (Figure 7, Table 3) while FASLG, HRK, ALAS2, SLC25A21, 304 CYP1B1, SNCA, MMP9, and OLFM4 were significantly downregulated (Figure 8, Table 3) 305 compared to controls. Two selected genes, LIG1 and MRPL51 did not show significant 306 dysregulation while LONP1 had a reverse expression in the validation compared to 307 transcriptomic expression profile. Upon comparison with TCGA dataset of adult AML 308 309 patients, similar dysregulation was observed for ALAS2, SLC25A21 and SLC25A29 genes while a reverse expression pattern was observed for ATP5J and CLIC1 genes; none of the 310 other genes showed significant dysregulation in the TCGA dataset (Table 3). 311

312 Mitochondria-related DEGs and mtDNA copy number

On univariable analysis, increased mtDNA copy number was significantly associated with 313 poor event free survival (HR= 2.14; 95%CI (1.39-3.29); p=0.001) and overall survival (HR= 314 2.77; 95% CI (1.70-4.59); p<0.001) (Figure 9). In patients with increased mtDNA copy 315 number, expression of SLC25A3, SDHC, RACK1/GNB2L1 and FASTKD1, were significantly 316 317 higher compared to those with low mtDNA copy number (Figure 10). Exclusive elevated expression of these 4 genes were also observed in transcriptome of samples with 318 high/intermediate mtDNA copy number(AMLCN H/AMLCN I) compared to low mtDNA 319 copy number (AMLCN_L).On correlation analysis, these 4 genes along with 2 other genes 320 *CLIC1* and *ATP5J* showed significant positive correlation with mtDNA copy number(Table 321 322 4).

323 Predictive ability of expression of validated DEGs on survival outcome and 324 establishment of the prognostic gene signature

On multivariable analysis, upregulated expression of 2 genes, SDHC (HR 1.29; 95% CI 325 (1.14-1.41); p<0.001) and *CLIC1*(HR 1.20; 95% CI (1.04-1.38); p=0.013), 326 and downregulation of *SLC25A29*(HR 0.88; 95% CI (0.83-0.93); p<0.001) were found to be 327 independently predictive of worse OS (Table 5) and they were included for the development 328 of a prognostic gene signature model. All these 3 genes (SDHC, CLIC1, SLC25A29) satisfied 329 330 internal validation by bootstrapping (Table S5), and were finally selected for prognostic model building. Beta coefficient of each of the variables were used for calculation of risk 331 score as follows: 332

 $Risk \ score = [(0.237 \times Expression \ SDHC) + (0.179 \times Expression \ CLIC1) + ((-0.131) \times Expression \ SLC25A29)] \times 100$

The formula was used to calculate risk score of all the patients. Risk score median value(10.382) was taken as the cut-off for subgrouping patients into high-risk and low risk group.

Patients with high-risk scores (≥ 10.382) had inferior OS (HR 1.010; 95% CI (1.007-1.014): 335 p<0.001) compared to those with low-risk score (<10.382) (Figure 11A). Harrel's C-index of 336 the prognostic model was 0.675. The timed AUC of the risk score for 12 months and 18 337 338 months survival was 0.747 and 0.736 respectively (Figure 11(B, C). Association of gene signature-based risk score with event free survival (EFS) 339 On multivariable Cox regression analysis, upregulation of SDHC (HR 1.225; 95% CI (1.100-340 1.363); p<0.001) and downregulation of SLC25A29 (HR 0.905; 95% CI (0.860-0.952); 341 342 p<0.001) were also predictive of worse EFS. We also found that patients with high-risk score had significantly lower EFS as compared to low-risk score patients (HR 1.008; 95% CI 343 (1.001-1.012); p<0.001) (Table 5). Harrel's C-index of prognostic model was 0.626. The 344 timed AUC of the risk score for 12 months and 18 months EFS was 0.617 and 0.612 345

346 respectively

Impact of baseline clinical features on survival outcome and association with gene signature model

On univariable Cox regression analysis, ELN intermediate/poor risk and absence of chloroma 349 were significantly associated with inferior OS and only ELN category came out to be an 350 independent prognostic factor in multivariable analysis (Table 6, Figure 11D). Furthermore, 351 on multivariable analysis, both the ELN risk category (p=0.040) and risk score (p<0.001) 352 353 were found to be independent prognostic factors for OS. We also performed multivariable analysis including mtDNA copy number and observed that all three factors i.e. risk score 354 (p<0.001), ENA risk categories(p=0.012) and mtDNA copy number(p=0.012) were 355 independent prognostic factors for OS (Table S6). 356

Impact of combined clinical and gene signature model on survival outcome of the cohort
To compare the predictive ability of our gene signature risk score and ELN risk stratification
on OS of AML patients, a time dependent AUC was constructed. Harrel's C-index of the

model was 0.59 and the timed AUC of ELN risk category on 12 months and 18 months survival was 0.60 and 0.64 respectively (Figure 11E, F). We combined the ELN risk strategy with our risk score and calculated the predictive ability of the model. The Harrel's C-index of the model was 0.688 and the timed AUC of combining ELN risk strategy with gene signature risk score for 12 months and 18 months was 0.761 and 0.765 respectively (Figure 11H and 2I).

366 Association of gene signature risk score on disease characteristics

We found that a high-risk score was significantly associated with poor risk cytogenetics(p=0.021), absence of RUNX1-RUNX1T1 translocation (p=0.027) and ELN intermediate/poor risk group (p=0.016). Furthermore, the proportion of patients achieving CR was significantly higher in the low-risk group as compared to the high-risk group(p=0.017) (Table 7). On subgroup analysis, it was observed that the mitochondria-related gene signature risk score category was significantly predictive of survival outcome across all clinically relevant subgroups except in those with intermediate/poor-risk karyotype (Figure 12).

374 Predictive ability of combined gene signature and ELN category model on survival 375 outcome

The predictive ability of gene signature score along with ELN risk stratification on survival 376 outcome of paediatric AML patients was also assessed. Patients with low gene signature 377 378 score (low risk) belonging to ELN good risk category had significantly better survival 379 outcome (Median OS: Not reached) and predicted 12-months (80%±6%), as well as 18months $(75\% \pm 7\%)$ survival. Similarly, patients with high gene signature score (high risk) 380 belonging to ELN intermediate/poor risk category had significantly inferior outcome (4.67 381 382 months (0-3.71)) with 12-months and 18-months predicted survival of 33% \pm 8% and 25% \pm 7% respectively. On the other hand, patients belonging to other groups (ELN 383 intermediate/poor risk and low-risk; ELN good risk and high-risk score) had intermediate 384

survival outcome (median survival of 27.77-22.90 months respectively) between the two
other groups (Figure 11G; Table 8).

387 External validation of gene signature risk score in TCGA database

388 Using our risk calculation model, we calculated the risk score in TCGA dataset (n=179) and similarly, patients were further sub-grouped as high-risk score (higher than median) and low 389 risk score (lower than median) based on the median value (43.434). Kaplan Meier analysis 390 391 showed that patients with a high-risk score (\geq 43.434) had inferior OS (HR 1.01;95% CI (1.00-1.02); p<0.019) compared to those with a low-risk score (<43.434) (Figure 11J; Table 392 393 5). Along with this, poor risk karyotype patients had worse overall survival (HR 1.89; 95% CI (2.95-1.20); p=0.004) compared to patients with good risk or intermediate risk karyotype 394 (7.03 vs 18.96months). On multivariable analysis karyotype (poor vs good risk/intermediate 395 396 risk) and risk score were found to be independently predictive of (p=0.002; p=0.025 397 respectively) for worse OS. The timed AUC of risk score for 12-months and 18-months survival in the TCGA dataset were 0.64 and 0.63 respectively (Figure 11K and 11L) and 398 399 Harrel's C-index of the prognostic model was 0.600.

400 Discussion

Our study is the first one to identify and validate mitochondria-related DEGs in paediatric 401 AML along with determining their prognostic significance. In paediatric AML patients, we 402 identified and validated 16 mitochondrial DEGs including 8 upregulated and 8 403 404 downregulated genes compared to controls. The dysregulated expression of these genes has been previously reported in the pathogenesis of various malignancies(20–23). However, they 405 have not been studied in paediatric AML. Comparison with LAML dataset of TCGA cohort 406 407 suggests that the mitochondria-related gene expression profile in paediatric AML is likely distinct. Elevated expression of genes like SLC25A3, FASTKD1, SDHC, ATP5J, which were 408 observed for the first time in our cohort, are involved in mitochondrial energy 409

410 metabolism(24-26). Genes like FASLG, HRK and SNCA, which were observed to be downregulated, also play role in prevention of mitochondrial damage and apoptosis inhibition 411 lines(27–29). 412 in melanoma/medulloblastoma cell Preliminary data suggests that downregulation of genes like MMP9 and OLFM4, as observed in our cohort, may aid in 413 AML progression(30,31). The expression of CYP1B1 is reported to be elevated in various 414 malignancies, however, its expression is downregulated in early age leukaemia, as seen in our 415 416 cohort(32). These findings suggest that the observed mitochondria-related DEGs likely play crucial role in disease progression in paediatric AML, which needs to be studied further 417 418 mechanistically.

Enhanced mtDNA copy number has been previously reported to be play role on AML 419 initiation, progression as well as predictive of survival outcomes(12,33). Similar to our 420 421 previous finding, we found that mtDNA copy number were significantly higher and independently predictive of worse survival outcome in this cohort of pediatric AML patients. 422 These findings emphasise the importance of mtDNA copy number as a driver of disease 423 biology. Among the 16 validated mitochondria-related DEGs analysed, we observed that the 424 patients with higher mtDNA copy number had significantly higher expression of SLC25A3, 425 426 SDHC, RACK1, and FASTKD1 compared to patients with low mtDNA copy number. While, only a small percentage of mitochondrial proteins are coded by the mitochondrial genome, 427 428 variations in mtDNA may modulate molecular signals through nuclear-mitochondrial crosstalk, which may promote tumorigenesis by upregulating oncogenes(34,35). This 429 suggests that in paediatric AML, cells with high mtDNA copy number are possibly driven 430 through unique gene expression alterations, influencing disease biology and therapeutic 431 response. 432

Comprehensive gene expression profiling has been extensively used to identify potentialprognostic genes in adult AML; however, dysregulation of mitochondria-related gene

expression, especially in children has not been well explored(36-38). Transcriptomic 435 profiling of cytogenetically normal paediatric AML has identified complex genomic 436 437 rearrangements and/or driver mutations in seemingly normal AML genomes and may even 438 aid risk stratification(39,40). Cai *et al.* developed a 3-gene prognostic risk model for children with AML using NCI TARGET dataset, although it was not externally validated(36). 439 Similarly, Duployez et al. and Jiang et al. developed leukaemia stem cell score gene 440 441 signature and immune checkpoint related gene signature respectively in paediatric AML predictive of survival outcomes(4,41). None of the above studies evaluated alterations in 442 443 mitochondrial gene expressions. Mitochondrial gene expression has been evaluated in other malignancies like ovarian cancer, where a mitochondria-related gene signature, consisting of 444 8 metabolic genes, has been identified with independent prognostic impact(42). 445

In this study, we identified exclusive mitochondria-related DEGs in paediatric AML and 446 developed a prognostic gene signature including 3 genes (SDHC, CLIC1, and SLC25A29). 447 The gene signature risk score was additionally found to be independently predictive of 448 survival along with established ELN risk stratification with improved predictive ability over 449 clinical risk categorization. The risk score was also found to be associated with poor clinical 450 features of AML like the absence of RUNX1-RUNX1T1 translocation or poor-risk 451 cytogenetics. Hence, the gene signature model is able to categorize the heterogenous 452 453 molecular landscape of AML into clinically meaningful categories along with identification of adverse disease biology. The developed prognostic score also has the potential to identify 454 high-risk subgroup even among those belonging to ELN good risk and vice-versa allowing 455 better upfront risk stratification and personalized treatment decisions. 456

457 TCGA LAML dataset has been extensively used for identifying as well as validating 458 prognostic gene signatures in various AML studies(43,44). We used the LAML dataset of 459 TCGA for external validation of our gene signature model and observed that the prognostic

gene signature score was also independently predictive of survival outcome in a large adult
cohort as well with predictive ability over and above known clinical predictors. This suggests
that the identified DEGs have a prognostic impact in AML across age group.

Our gene signature included 3 mitochondria-related genes i.e., SDHC, CLIC1, and 463 SLC25A29. SDH mutations lead to decreased activity of SDH with accumulation of succinate 464 465 and increase in oxidative stress resulting in DNA damage and tumorigenesis(45). In contrast to previous findings, which suggests that the SDH gene is inactivated in solid tumors(46), we 466 observed an increased expression of SDHC gene in AML which was predictive of worse 467 survival. This is likely because, in contrast to solid malignancies, aggressive leukemias like 468 AML depend on cellular oxidative phosphorylation for proliferation which is supported by 469 upregulation of respiratory complex genes(47). Various studies also suggest dysregulation of 470 chloride ion channels such as the *CLIC1* gene which plays a role in drug resistance and 471 progression of various malignancies(22,48). Although, the role of CLIC1 in AML is still 472 unexplored, we observed significant upregulation of *CLIC1* in paediatric AML with adverse 473 prognostic impact. The downstream effects of upregulation of CLIC1 on disease biology of 474 AML need to be further deciphered. 475

In the current study, we observed an upregulation of *SLC25A29* in our cohort of paediatric 476 AML patients, which is in line with previous studies where it was found to be significantly 477 478 elevated in multiple malignancies(23). Similar upregulation was also been observed in adult AML patients of TCGA LAML dataset. However, on survival analysis, downregulation of 479 SLC25A29 was independently predictive of worse OS in our cohort. This finding was 480 consistent even in the external cohort of TCGA LAML dataset, where even though the 481 expression of SLC25A29 was upregulated, a downregulated expression was predictive of 482 worse survival outcomes. This finding was intriguing and the mechanism by which 483 downregulation of SLC25A29 drives a worse survival outcome remains unclear. SLC25A29 is 484

the main arginine transporter in the mitochondrial membrane(49). Aberrant upregulation of 485 SLC25A29 may result in transportation of more arginine into mitochondria, promoting 486 synthesis of metabolites like nitric oxide, polyamines, proline and creatine, which are 487 488 essential for cell survival and proliferation(50). Mitochondria-derived nitric oxide is known to have a dichotomous role in regulation of cancer progression which is influenced by 489 expression of SLC25A29likelyaffecting disease outcome(51). The SLC25 family of genes 490 which encodes for a set of mitochondrial inner membrane carrier proteins, have been 491 identified as a potential biomarker as well as novel therapeutic targets in various 492 493 malignancies(52). The implications of altered expression of SLC25A29 on disease biology of AML and its assessment as a therapeutic target is an exciting area of further research. 494

495 Our study has certain limitations. Transcriptomic profile and further validation by RTPCR 496 were done in whole isolated mononuclear cell and not in sorted blasts. Initial selection of 497 DEGs were also done from whole RNA sequencing of a limited number of samples, which 498 may lead to a bias in selection, however, external validation of the validated genes confirmed 499 their prognostic impact in an independent cohort.

In conclusion, this is the first study to report a validated set of mitochondria-related DEGs in 500 paediatric AML. We observed that patients with high mtDNA copy number have a unique 501 gene expression pattern possibly affecting disease biology. We developed a 3-gene based 502 503 mitochondrial gene signature model with ability to predict prognosis in paediatric AML patients over and above established clinical prognostic parameters. The gene signature was 504 also externally validated in a cohort of adult AML patients demonstrating its predictive 505 ability in adult AML as well. Further directions for research include in vitro studies for 506 elucidating the role of prognostic genes in leukemogenesis and their evaluation as potential 507 targets for the treatment of paediatric AML. 508

509 **Data availability statement**

The sequencing data is publicly available in repository (NCBI-SRA at PRJNA778747) and
rest of data is available from the principal investigator on reasonable request.

512 Acknowledgements

The authors acknowledge the funding support from DST-SERB (Department of Science and 513 Technology - Science and Engineering Research Board), Government of India for this work. 514 (Extramural EMR/2016/006376 Research 515 Research grant: and Core grant: CRG/2021/001887). The authors acknowledge the funding support from ICMR (Indian 516 517 Council of Medical Research), Government of India for this work (ICMR SRF: 2019-6059/CMB/BMS). The authors also acknowledge every member of paediatric oncology team 518 of our centre including research staff, nurses and dietician for their exemplary clinical 519 520 services.

521 Authorship Contribution Statement

522 Shilpi Chaudhary conceptualized the study, conducted the research, performed data analysis and interpreted results and wrote the manuscript. Shuvadeep Ganguly analysed data, 523 interpreted results and wrote the manuscript. Jayanth Kumar Palanichamy, Archna Singh, 524 525 Radhika Bakhshi and Anita Chopra conceptualized the study, provided intellectual inputs, administrative support and edited the manuscript. Dibyabhaba Pradhan conducted 526 transcriptome data analysis. Sameer Bakhshi conceptualized the study, provided 527 528 administrative support, intellectual inputs, interpreted results, wrote and edited the manuscript. All authors have reviewed and approved the final version of the manuscript. 529

530 **Conflict of interest declaration statement**

531 All authors declare no potential conflicts of interest.

533 **References**

534	1.	Lonetti A, Pession A, Masetti R. Targeted Therapies for Pediatric AML: Gaps and
535		Perspective [Internet]. Vol. 7, Frontiers in Pediatrics. Frontiers Media S.A.; 2019
536		[cited 2020 Nov 27]. p. 463. Available from: www.frontiersin.org
537	2.	Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al.
538		Diagnosis and management of AML in adults: 2017 ELN recommendations from an
539		international expert panel [Internet]. Vol. 129, Blood. American Society of
540		Hematology; 2017 [cited 2021 Apr 10]. p. 424-47. Available from:
541		http://ashpublications.org/blood/article-pdf/129/4/424/1402046/blood733196.pdf
542	3.	Elsayed AH, Rafiee R, Cao X, Raimondi S, Downing JR, Ribeiro R, et al. A six-gene
543		leukemic stem cell score identifies high risk pediatric acute myeloid leukemia.
544		Leukemia [Internet]. 2020 Mar 1 [cited 2021 Feb 1];34(3):735-45. Available from:
545		https://doi.org/10.1038/s41375-019-0604-8
546	4.	Duployez N, Marceau-Renaut A, Villenet C, Petit A, Rousseau A, Ng SWK, et al.
547		Evaluation of gene expression signatures predictive of cytogenetic and molecular
548		subtypes of pediatric acute myeloid leukemia. Leukemia [Internet]. 2019 Feb 1 [cited
549		2021 Aug 3];33(2):348–57. Available from:
550		https://haematologica.org/article/view/5869
551	5.	Wagner S, Vadakekolathu J, Tasian SK, Altmann H, Bornhäuser M, Pockley AG, et al.
552		A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid
553		leukemia multicohort study. Blood Adv [Internet]. 2019 Apr 23 [cited 2021 Aug
554		5];3(8):1330–46. Available from: http://www.vizome.org/aml/
555	6.	Weinberg SE, Chandel NS. Targeting mitochondria metabolism for cancer therapy
556		[Internet]. Vol. 11, Nature Chemical Biology. Nature Publishing Group; 2015 [cited
557		2020 Aug 27]. p. 9–15. Available from: /pmc/articles/PMC4340667/?report=abstract

- 558 7. Panina SB, Baran N, Brasil da Costa FH, Konopleva M, Kirienko N V. A mechanism
- 559 for increased sensitivity of acute myeloid leukemia to mitotoxic drugs. Cell Death Dis
- 560 [Internet]. 2019 Aug 1 [cited 2020 Aug 13];10(8):1–15. Available from:
- 561 https://doi.org/10.1038/s41419-019-1851-3
- 562 8. Al Ageeli E. Alterations of mitochondria and related metabolic pathways in leukemia:
- A narrative review. Saudi J Med Med Sci [Internet]. 2020 [cited 2020 Aug 16];8(1):3.

564 Available from: /pmc/articles/PMC6945320/?report=abstract

- 565 9. Tyagi A, Pramanik R, Bakhshi R, Singh A, Vishnubhatla S, Bakhshi S. Expression of
- 566 mitochondrial genes predicts survival in pediatric acute myeloid leukemia. Int J
- 567 Hematol [Internet]. 2019 Aug 5 [cited 2020 Jul 21];110(2):205–12. Available from:
- 568 https://doi.org/10.1007/s12185-019-02666-2
- 10. Tyagi A, Pramanik R, Vishnubhatla S, Bakhshi R, Bakhshi S. Prognostic impact of
- 570 mitochondrial DNA D-loop variations in pediatric acute myeloid leukemia. Oncotarget
- 571 [Internet]. 2019 Feb 1 [cited 2020 Aug 14];10(13):1334–43. Available from:
- 572 /pmc/articles/PMC6407682/?report=abstract
- 573 11. Sharawat SK, Bakhshi R, Vishnubhatla S, Bakhshi S. Mitochondrial D-loop variations
- 574 in paediatric acute myeloid leukaemia: A potential prognostic marker. Br J Haematol
- 575 [Internet]. 2010 May 1 [cited 2021 Apr 12];149(3):391–8. Available from:
- 576 http://doi.wiley.com/10.1111/j.1365-2141.2010.08084.x
- 577 12. Chaudhary S, Ganguly S, Palanichamy JK, Singh A, Bakhshi R, Jain A, et al. PGC1A
- driven enhanced mitochondrial DNA copy number predicts outcome in pediatric acute
- 579 myeloid leukemia. Mitochondrion [Internet]. 2021 May 1 [cited 2021 Apr 14];58:246–
- 580 54. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1567724921000453
- 13. Arora S, Pushpam D, Tiwari A, Choudhary P, Chopra A, Gupta R, et al. Allogeneic
- hematopoietic stem cell transplant in pediatric acute myeloid leukemia: Lessons learnt

583		from a tertiary care center in India. Pediatr Transplant [Internet]. 2020 [cited 2021 Apr
584		12]; Available from: https://pubmed.ncbi.nlm.nih.gov/33142026/
585	14.	Tyagi A, Pramanik R, Chaudhary S, Chopra A, Bakhshi S. Cytogenetic Profiles of 472
586		Indian Children with Acute Myeloid Leukemia. Indian Pediatr. 2018;55(6):469–73.
587	15.	Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al.
588		STRING v9.1: protein-protein interaction networks, with increased coverage and
589		integration. Nucleic Acids Res. 2012 Nov;41(D1):D808–15.
590	16.	Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: Identifying hub
591		objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(4):S11.
592	17.	Bader GD, Hogue CWV. An automated method for finding molecular complexes in
593		large protein interaction networks. BMC Bioinformatics. 2003 Jan;4:2.
594	18.	Binder JX, Pletscher-Frankild S, Tsafou K, Stolte C, O'Donoghue SI, Schneider R, et
595		al. COMPARTMENTS: Unification and visualization of protein subcellular
596		localization evidence. Database [Internet]. 2014 [cited 2021 Jun 3];2014. Available
597		from: /pmc/articles/PMC3935310/
598	19.	Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: A web server for cancer and
599		normal gene expression profiling and interactive analyses. Nucleic Acids Res
600		[Internet]. 2017 Jul 3 [cited 2021 Jun 4];45(W1):W98–102. Available from:
601		https://pubmed.ncbi.nlm.nih.gov/28407145/
602	20.	Li J-J, Xie D. RACK1, a versatile hub in cancer. Oncogene 2015 3415 [Internet]. 2014
603		Jun 2 [cited 2021 Jul 12];34(15):1890–8. Available from:
604		https://www.nature.com/articles/onc2014127
605	21.	Oehler VG, Ka YY, Choi YE, Bumgarner RE, Raftery AE, Radich JP. The derivation
606		of diagnostic markers of chronic myeloid leukemia progression from microarray data.
607		Blood. 2009;114(15):3292–8.

608	22.	Lee JR, Lee JY, Kim HJ, Hahn MJ, Kang JS, Cho H. The inhibition of chloride
609		intracellular channel 1 enhances Ca2+ and reactive oxygen species signaling in A549
610		human lung cancer cells. Exp Mol Med [Internet]. 2019 Jul 1 [cited 2020 Sep
611		25];51(7):1-11. Available from: https://doi.org/10.1038/s12276-019-0279-2
612	23.	Zhang H, Wang Q, Gu J, Yin L, Liang S, Wu L, et al. Elevated mitochondrial
613		SLC25A29 in cancer modulates metabolic status by increasing mitochondria-derived
614		nitric oxide. Oncogene. 2018 May;37(19):2545-58.
615	24.	Kolbe HVJ, Costello D, Wong A. Mitochondrial phosphate transport. Large scale
616		isolation and characterization of the phosphate transport protein from beef heart
617		mitochondria. J Biol Chem [Internet]. 1984 [cited 2021 Jul 9];259(14):9115-20.
618		Available from: https://www.jbc.org/article/S0021-9258(17)47273-5/abstract
619	25.	Nazar E, Khatami F, Saffar H, Tavangar SM. The Emerging Role of Succinate
620		Dehyrogenase Genes (SDHx) in Tumorigenesis. Int J Hematol Stem Cell Res
621		[Internet]. 2019 [cited 2021 Jul 12];13(2):72. Available from:
622		/pmc/articles/PMC6660475/
623	26.	AA J, J P, MA de la F, JC M, P A, M S. The FASTK family of proteins: emerging
624		regulators of mitochondrial RNA biology. Nucleic Acids Res [Internet]. 2017 Nov 2
625		[cited 2021 Jul 12];45(19):10941–7. Available from:
626		https://pubmed.ncbi.nlm.nih.gov/29036396/
627	27.	M C, W W, J M, P Y, K W. High glucose induces mitochondrial dysfunction and
628		apoptosis in human retinal pigment epithelium cells via promoting SOCS1 and
629		Fas/FasL signaling. Cytokine [Internet]. 2016 Feb 1 [cited 2021 Jul 13];78:94-102.
630		Available from: https://pubmed.ncbi.nlm.nih.gov/26700587/
631	28.	Li Y, Yu Z, Jiang T, Shao L, Liu Y, Li N, et al. SNCA, a novel biomarker for Group 4
632		medulloblastomas, can inhibit tumor invasion and induce apoptosis. Cancer Sci

633	[Internet]. 2018 A	pr 1 [cited 2021 Ju	1 13];109(4):1263.	Available from:
-----	--------------------	---------------------	--------------------	-----------------

- 634 /pmc/articles/PMC5891175/
- 635 29. Rizvi F, Heimann T, Herrnreiter A, O'Brien WJ. Mitochondrial Dysfunction Links
- 636 Ceramide Activated HRK Expression and Cell Death. PLoS One [Internet]. 2011
- 637 [cited 2021 Jul 13];6(3):e18137. Available from:
- https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0018137
- 639 30. Lin LI, Lin DT, Chang CJ, Lee CY, Tang JL, Tien HF. Marrow matrix
- 640 metalloproteinases (MMPS) and tissue inhibitors of MMP in acute leukaemia:
- 641 Potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients
- with acute myelogenous leukaemia. Br J Haematol [Internet]. 2002 Jun 1 [cited 2021
- 643 Jan 25];117(4):835–41. Available from: http://doi.wiley.com/10.1046/j.1365-
- 644 2141.2002.03510.x
- 645 31. Liu W, Lee HW, Liu Y, Wang R, Rodgers GP. Olfactomedin 4 is a novel target gene
- of retinoic acids and 5-aza-2'-deoxycytidine involved in human myeloid leukemia cell
- growth, differentiation, and apoptosis. Blood [Internet]. 2010 Dec 2 [cited 2021 Jul
- 648 13];116(23):4938–47. Available from: https://www.meta.org/papers/olfactomedin-4-
- 649 is-a-novel-target-gene-of-retinoic/20724538
- 650 32. Lopes BA, Emerenciano M, Gonçalves BAA, Vieira TM, Rossini A, Pombo-de-
- 651 Oliveira MS. Polymorphisms in CYP1B1, CYP3A5, GSTT1, and SULT1A1 are
- associated with early age acute leukemia. Kanungo J, editor. PLoS One [Internet].
- 653 2015 May 18 [cited 2021 Feb 1];10(5):e0127308. Available from:
- 654 https://dx.plos.org/10.1371/journal.pone.0127308
- 655 33. Kang MG, Kim YN, Lee JH, Szardenings M, Baek HJ, Kook H, et al.
- 656 Clinicopathological implications of mitochondrial genome alterations in pediatric
- acute myeloid leukemia. Ann Lab Med [Internet]. 2016 Mar 1 [cited 2020 Jul

658		23];36(2):101-10. Available from: https://pubmed.ncbi.nlm.nih.gov/26709256/
659	34.	Pagliarini DJ, Calvo SE, Chang B, Sheth SA, Vafai SB, Ong SE, et al. A
660		Mitochondrial Protein Compendium Elucidates Complex I Disease Biology. Cell.
661		2008 Jul 11;134(1):112–23.
662	35.	Horan MP, Cooper DN. The emergence of the mitochondrial genome as a partial
663		regulator of nuclear function is providing new insights into the genetic mechanisms
664		underlying age-related complex disease [Internet]. Vol. 133, Human Genetics. Hum
665		Genet; 2014 [cited 2021 Jul 9]. p. 435-58. Available from:
666		https://pubmed.ncbi.nlm.nih.gov/24305784/
667	36.	Cai Z, Wu Y, Zhang F, Wu H. A three-gene signature and clinical outcome in pediatric
668		acute myeloid leukemia. Clin Transl Oncol [Internet]. 2020 Aug 29 [cited 2021 Feb 1];
669		Available from: http://link.springer.com/10.1007/s12094-020-02480-x
670	37.	Duployez N, Marceau-Renaut A, Villenet C, Petit A, Rousseau A, Ng SWK, et al. The
671		stem cell-associated gene expression signature allows risk stratification in pediatric
672		acute myeloid leukemia. Leukemia [Internet]. 2019 Feb 1 [cited 2021 Feb
673		1];33(2):348–57. Available from: https://doi.org/10.1038/s41375-018-0227-5
674	38.	Nguyen CH, Glüxam T, Schlerka A, Bauer K, Grandits AM, Hackl H, et al. SOCS2 is
675		part of a highly prognostic 4-gene signature in AML and promotes disease
676		aggressiveness. Sci Rep [Internet]. 2019 Dec 1 [cited 2021 Feb 1];9(1):1-13. Available
677		from: https://doi.org/10.1038/s41598-019-45579-0
678	39.	Shiba N, Yoshida K, Hara Y, Yamato G, Shiraishi Y, Matsuo H, et al. Transcriptome
679		analysis offers a comprehensive illustration of the genetic background of pediatric
680		acute myeloid leukemia. Blood Adv [Internet]. 2019 Oct 22 [cited 2021 Aug
681		16];3(20):3157–69. Available from: /pmc/articles/PMC6849955/
682	40.	Balgobind B V., van den Heuvel-Eibrink MM, De Menezes RX, Reinhardt D, Hollink

- 683 IHI, Arentsen-Peters STJCM, et al. Evaluation of gene expression signatures
- 684 predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia.
- 685 Haematologica. 2011 Feb;96(2):221–30.
- 41. Jiang F, Wang XY, Wang MY, Mao Y, Miao XL, Wu CY, et al. An Immune
- 687 Checkpoint-Related Gene Signature for Predicting Survival of Pediatric Acute
- 688 Myeloid Leukemia. J Oncol. 2021;2021.
- 42. Wang L, Li X. Identification of an energy metabolism-related gene signature in
- 690 ovarian cancer prognosis. Oncol Rep [Internet]. 2020 Jun 1 [cited 2021 Feb
- 691 2];43(6):1755–70. Available from: http://www.affymetrix.
- 43. Zhang Y, Ma S, Wang M, Shi W, Hu Y. Comprehensive Analysis of Prognostic
- Markers for Acute Myeloid Leukemia Based on Four Metabolic Genes. Front Oncol.
 2020 Sep 29:0:1990.
- 695 44. Huang R, Liao X, Li Q. Identification and validation of potential prognostic gene
- biomarkers for predicting survival in patients with acute myeloid leukemia. Onco
- Targets Ther [Internet]. 2017 Nov 2 [cited 2021 Aug 3];10:5243. Available from:
- 698 /pmc/articles/PMC5679677/
- 45. Zhao T, Mu X, You Q. Succinate: An initiator in tumorigenesis and progression
- [Internet]. Vol. 8, Oncotarget. Impact Journals, LLC; 2017 [cited 2021 Aug 16]. p.
- 701 53819–28. Available from: /pmc/articles/PMC5581152/
- 46. Li J, Liang N, Long X, Zhao J, Yang J, Du X, et al. SDHC-related deficiency of SDH
- complex activity promotes growth and metastasis of hepatocellular carcinoma via
- 704 ROS/NFκB signaling. Cancer Lett. 2019 Oct;461:44–55.
- 47. Panina SB, Pei J, Kirienko N V. Mitochondrial metabolism as a target for acute
- 706 myeloid leukemia treatment [Internet]. Vol. 9, Cancer & Metabolism. Springer Science
- and Business Media LLC; 2021 [cited 2021 May 26]. p. 1–25. Available from:

708 https://doi.org/10.1186/s40170-021-00253-w

- 48. He YM, Zhang ZL, Liu QY, Xiao YS, Wei L, Xi C, et al. Effect of CLIC1 gene
- silencing on proliferation, migration, invasion and apoptosis of human gallbladder

711 cancer cells. J Cell Mol Med. 2018 May;22(5):2569–79.

- 49. Porcelli V, Fiermonte G, Longo A, Palmieri F. The human gene SLC25A29, of solute
- carrier family 25, encodes a mitochondrial transporter of basic amino acids. J Biol
- 714 Chem. 2014 May;289(19):13374–84.
- 50. Keshet R, Erez A. Arginine and the metabolic regulation of nitric oxide synthesis in
- cancer [Internet]. Vol. 11, DMM Disease Models and Mechanisms. Company of
- 717 Biologists; 2018 [cited 2021 Aug 19]. Available from: /pmc/articles/PMC6124554/
- 71851.Ghafourifar P, Cadenas E. Mitochondrial nitric oxide synthase. Vol. 26, Trends in

719 Pharmacological Sciences. Elsevier Ltd; 2005. p. 190–5.

- 52. Rochette L, Meloux A, Zeller M, Malka G, Cottin Y, Vergely C. Mitochondrial
- 721 SLC25 carriers: Novel targets for cancer therapy. Vol. 25, Molecules. MDPI AG;
- 722 2020.
- 723

725 Figures



726

Figure 1. Workflow of the study: Study workflow showing flow of patients from enrolment to
RNA sequencing, identification of mitochondria- related DEGs, development and validation of novel
3-gene based Risk score.





731	Figure 2:	Workflow of	f RNA se	quencing	data anal	ysis using	various	bioinf	ormatic to	ols
-						,				

Figure 3



735

Figure 3: Volcano plots representing all dysregulated transcripts among AMLCN_H (A),
AMLCN_I (B) and AMLCN_L (C) groups compared to controls. Green dots represent
significantly differentially expressed transcripts in the three subgroups of AML compared to
controls. High AMLCN_H (more than 75th percentile); intermediate AMLCN_I (50th to 75th
percentile) and low AMLCN_L (lower than 50th percentile) relative mitochondrial DNA copy number





743

744

Figure 4: Venn diagram representing mitochondrial associated differentially expressed genes (DEGs)
among three groups of AML (AMLCN_H; AMLCN_I and AMLCN_L). High AMLCN_H (more

than 75th percentile); intermediate AMLCN_I (50th to 75th percentile) and low AMLCN_L (lower than

748 50th percentile) relative mitochondrial DNA copy number

749

750





752

753

- **Figure 5**: Hub gene based on Maximal Clique Centrality (MCC) (A): AMLCN_H; (B) AMLCN_I;
- 755 (C) AMLCN_L. High AMLCN_H (more than 75th percentile); intermediate AMLCN_I (50th to 75th
- 756 percentile) and low AMLCN_L (lower than 50th percentile) relative mitochondrial DNA copy number

757

Figure 6



759

Figure 6: MCODE (molecular complex detection) analysis showing most interactive clusters
among A: (A): AMLCN_H; (B) AMLCN_I; (C) AMLCN_L. High AMLCN_H (more than 75th
percentile); intermediate AMLCN_I (50th to 75th percentile) and low AMLCN_L (lower than 50th
percentile) relative mitochondrial DNA copy number

764



Figure 7: Validation of selected upregulated differentially expressed genes (DEGs) in patients as
compared to controls. *SLC25A3*, *SLC25A29*, *SDHC*, *FASTKD1*, *GLUD1*, *RACK1*, *ATP5J* and *CLIC1*were significantly upregulated in pediatric AML patients (n=143) compared to controls (n=50). *:
P<0.05; **: P< 0.01; ***: P<0.001; ****: P<0.0001.



Figure 8: Validation of selected downregulated differentially expressed genes (DEGs) in patients as
compared to controls. *FASLG, CYP1B1, HRK, ALAS2, SLC25A21, MMP9, SNCA* and *OLFM4* were
significantly downregulated in pediatric AML patients (n=143) compared to controls (n=50) *:
P<0.05; **: P< 0.01; ***: P<0.001; ****: P<0.001

Figure 9



785

Figure 9: Kaplan Meier curves representing association of mtDNA copy number with (A) event freesurvival and (B) overall survival of pediatric AML patients



Figure 10: Subgroup analysis of acute myeloid leukemia showing exclusive deregulation of validated
genes among AMLCN_L and AMLCN_H group. The expression of *SLC25A3*(A), *SDHC*(B), *RACK1*(C) and *FASTKD1*(D) were significantly higher in AMLCN_H group as compared to
AMLCN_L



Figure 11: Kaplan Meier curves representing association of mtDNA copy number with (A) event free survival and (B) overall survival of pediatric AML patients Figure 11.A 3-gene based gene signature stratifies survival in pediatric and adult AML patients along with clinically established European LeukemiaNet (ELN) risk categories. (A) Kaplan Meier estimates of overall survival in pediatric AML patient's subgroup into high Risk-score and low Risk-score. (B) and (C) AUC curves quantify the ability of our 3-gene based risk score to predict outcome in individual patients (specificity and sensitivity) within the first 12 months(B) and 18 months(C) of treatment initiation respectively. (D) Kaplan Meier estimates of overall survival in pediatric AML patient's subgroup into ELN good risk and ELN intermediate or poor risk categories. (E) and (F) AUC curves quantify the ability of ELN risk categories to predict outcome in individual patients (specificity and sensitivity) within the first 12 months (E) and 18 months(F) of treatment initiation respectively. (G) Kaplan Meier estimates of overall survival in pediatric AML patient's subgroup by combining ELN risk categories with our 3 gene-based risk score. (H) and (I) AUC curves quantify the ability of combined model of ELN risk categories and our 3 gene-based risk score to predict outcome in individual patients (specificity and sensitivity) within the first 12 months(H) and 18 months(I) of treatment initiation respectively. (J) Kaplan Meier estimates of overall survival in external adult The Cancer Genome Atlas (TCGA) AML patient's subgroup into high Risk-score and low Risk-score using our 3 gene-based gene signature model. (K) and (L) AUC curves quantify the ability of our 3-gene based risk score to predict outcome in individual patients of TCGA adult AML datasets (specificity and sensitivity) within the first 12 months(K) and 18 months(L) of treatment initiation respectively. AUC = 1.0 would denote perfect prediction, and AUC = 0.5 would denote no predictive ability.



Figure 12: Forest plot showing the impact of mitochondrial prognostic gene signature risk score
category on survival outcome in various clinically relevant subgroups of pediatric Acute myeloid
leukemia

Characteristics	Number (%)
Median age (years)	10 (0.8-18)
Sex	·
Male	87 (60.8)
Female	56 (39.2)
Haematological parameters	
Median haemoglobin, (g/dL)	7.4 (2.1-14.6)
Median total leucocyte count, (×10 ³ /µL)	24.38 (0.76-314.3)
Hyperleukocytosis, (> $50 \times 10^3 / \mu L$)	45 (31.46)
Median platelet count, (×10 ³ / μ L)	35.00(4-276)
Clinical features at presentation	
Fever	112(78.3)
Chloroma	27 (18.9)
Cytogenetics (n=130)	·
Normal	36 (27.5)
t(8;21) & inv (16)*	52 (39.7)
Complex karyotype	8 (6.1)
Other	19 (14.5)
Failed cytogenetics	16(12.2)
Molecular analysis (n= 122)	·
FLT3 ITD	17 (13.8)
RUNX1-RUNX1T1	53 (43.1)
CBFB-MYH11	6 (4.9)
NPM1	5 (4.1)
Negative	41 (33.6)
ELN risk stratification** (n=134)	·
Good	67 (50)
Intermediate	37 (27.6)
Poor	30 (22.4)
Complete remission (n=143)	
Achieved	104 (72.7%)
Not achieved	39 (27.3%)

841 Table 1: Baseline characteristic features of pediatric AML patients (n=143)

842 * t(8;21)= t(8;21)(q22;q22) *RUNX1-RUNX1T1*; inv(16)= inv(16)(p13.1;q22) *CBFB-MYH11*

- **ELN risk stratification was done using both cytogenetics and molecular markers in 134 patients. However,
 for 12 patients risk stratification was done with only cytogenetics and in 20 patients, it was done by only
- 845 molecular analysis.
- 846 Median values were reported with range

n: number of patients; AML: Acute Myeloid Leukemia; Normal cytogenetics: 46,XX/46,XY; Failed
cytogenetics: metaphases could not be isolated; *FLT3 ITD*: FMS-like tyrosine kinase internal tandem

- 849 duplication; *RUNX1-RUNX1T1*: runt-related transcription factor 1-RUNX1 partner transcriptional co-repressor
- 850 1 fusion transcript; *CBFB-MYH11*: core binding factor beta-myosin heavy chain 11 fusion transcript; *NPM1*:
- 851 Nucleophosmin 1; ELN: European LeukemiaNet.
- 852

S no.	Gene name	Compartment mitochondria score (0-5)	Groupwise expression	Expression in RNA seq data
1	SLC25A3	5	AMLCN_H	Upregulation
2	LONP1	5	AMLCN_H	Downregulation
3	SDHC	5	AMLCN_H	Upregulation
4	GNB2L1/RACK1	4.2	AMLCN_H	Upregulation
5	FASTKD1	5	AMLCN_I	Upregulation
6	MRPL51	5	AMLCN_I	Downregulation
7	ATP5J	5	AMLCN_I	Upregulation
8	FASLG	2.64	AMLCN_L	Downregulation
9	CLIC1	3.12	AMLCN_L	Upregulation
10	HRK	5	Common in all AML samples	Downregulation
11	ALAS2	5	Common in all AML samples	Downregulation
12	SLC25A21	5	Common in all AML samples	Downregulation
13	CYP1B1	4.35	Common in all AML samples	Downregulation
14	GLUD1	5	Common in AMLCN_H & AMLCN_I	Upregulation
15	SLC25A29	5	Common in AMLCN_H & AMLCN_I	Upregulation
16	LIG1	3.6	Common in AMLCN_H & AMLCN_I	Downregulation
17	SNCA	4.6	Common in AMLCN_L & AMLCN_H	Downregulation
18	DHFR	4.7	Common in AMLCN_L & AMLCN_H	Downregulation
19	ММР9	2.8	Hub gene and Seed gene in MCODE cluster of AMLCN_H & AMLCN_I	Downregulation
20	OLFM4	5	MCODE cluster gene	Downregulation

854	Table 2: List of genes selected for validation among all the groups based on mitochondrial
855	compartment score, Cytohubba and MCODE

All the genes selected for validation are listed in the table. Selection of genes were based on their mitochondrial compartment score as determined by *Cytoscape*. *SLC25A3*, *LONP1*, *SDHC*, *GNB2L1/RACK1* were selected exclusively from AMLCN_H subgroup. Three genes (*FASTKD1*, *MRPL51* AND ATP6J) belongs to AMLCN_I subgroup and two genes (*FASLG & CLIC1*) were selected from AMLCN_L subgroup. Furthermore, three genes (*SLC25A29*, *GLUD1* and *LIG1*) which were common among AMLCN_H and AMLCN_I and two genes, *DHFR* and *SNCA* were selected from the common genes among AMLCN_H and AMLCN_L cohort. *MMP9* and *OLFM4* were selected based on the Hub gene and MCODE analysis.

863

Table 3: Median expression of validated genes in patients (n=143) compared to controls(n=50) and their comparison with TCGA LAML dataset(n=179)

S.n o.	Gene list	Expression	Median expression $(IQR)^{\#}$	P value ^{##}	Expression in our cohort	Expression in TCGA dataset (LAML)*
1.	SLC25A3	Patients	7.45E-04 (5.46E-04-1.08E-03)	< 0.0001	Overexpression	Non-significant
		Controls	4.83E-04(3.08E-04-6.95E-04)			
2.	SDHC	Patients	1.03E-04(7.21E-05-1.66E-04)	< 0.0001	Overexpression	Non-significant
		Controls	5.13E-05(3.39E-05-7.81E-05)			
3.	RACK1/	Patients	1.56E-02(1.07E-02-2.26E-02)	< 0.0001	Overexpression	Non-significant
	GND2L1	Controls	6.43E-03(4.12E-03-9.42E-03)			
4.	FASTKD1	Patients	6.10E-04(3.75E-04-1.09E-03)	< 0.0001	Overexpression	Non-significant
		Controls	2.71E-04(1.60E-04-5.06E-04)			
5.	ATP5J	Patients	2.67E-06(1.48E-06-4.23E-06)	< 0.0001	Overexpression	Downregulation
		Controls	5.63E-07(1.44E-07 -1.04E-06)			
6.	FASLG	Patients	1.24E-05(5.82E-06-2.23E-05)	< 0.0001	Downregulation	Non-significant
		Controls	2.83E-05(1.72E-05-5.11E-05)			
7.	CLICI	Patients	9.63E-04(6.70E-04-1.48E-03)	< 0.0001	Overexpression	Downregulation
		Controls	5.46E-04(3.68E-04-7.91E-04)			
8.	HRK	Patients	2.99E-06(1.30E-06-7.32E-06)	< 0.0001	Downregulation	Non-significant
		Controls	2.64E-05(7.26E-06-4.44E-05)			
9.	ALAS2	Patients	9.00E-05(1.68E-05-4.16E-04)	< 0.0001	Downregulation	Downregulation
		Controls	7.61E-04(4.68E-04-1.71E-03)			
10.	SLC25A21	Patients	2.27E-06(6.51E-07-7.02E-06)	< 0.0001	Downregulation	Downregulation
		Controls	8.28E-05(3.86E-05-1.32E-04)			
11.	CYP1B1	Patients	4.87E-07(1.94E-07-1.87E-06)	< 0.0001	Downregulation	Non-significant
		Controls	4.57E-06(3.22E-06-1.05E-05)			
12.	GLUT1	Patients	5.46E-04(3.88E-04-8.10E-04)	< 0.0001	Overexpression	Non-significant
		Controls	2.65E-04(1.91E-04-4.08E-04)			
13.	SLC25A29	Patients	3.48E-04(1.94E-04-6.53E-04)	< 0.0001	Overexpression	Upregulation
		Controls	7.30E-05(5.35E-05-1.26E-04)			
14.	SNCA	Patients	5.73E-05(2.30E-05-1.59E-04)	0.0023	Downregulation	Non-significant
		Controls	1.06E-04(5.29E-05-2.25E-04)			
15.	DHFR	Patients	5.01E-04(2.58E-04-7.72E-04)	0.0115	Non- significant	Non-significant
		Controls	7.15E-04(4.32E-04-1.25E-03)			
16.	ММР9	Patients	2.70E-05(7.74E-06-7.15E-05)	< 0.0001	Downregulation	Non-significant
		Controls	9.05E-04(3.79E-04-1.37E-03)			
17.	OLFM4	Patients	3.78E-05(1.16E-05-1.47E-04)	< 0.0001	Downregulation	Non-significant
		Controls	9.37E-04(4.46E-04-2.54E-03)			
18.	LIG1	Patients	1.57E-04(9.12E-05- 2.46E-04)	0.8696	Non- significant	Non-significant
		Controls	1.38E-04(1.06E-04- 2.46E-04)			
19.	MRPL51	Patients	6.95E-04(5.46E-04-1.07E-03)	0.0116	Non- significant	Downregulation
		Controls	5.25E-04 (3.56E-04-1.00E-03)			
20.	LONP1	Patients	2.93E-04(2.10E-04-4.11E-04)	< 0.0001**	Upregulation	Downregulation
		Controls	1.79E-04(1.03E-04-2.59E-04)			

- 868 [#]IQR= Interquartile Range
- 869 ^{##}Level of significance was set by adjusting alpha error for multiple comparisons by Bonferroni correction (p<
- 870 (0.05/20) i.e. p<0.0025 were considered as significant)
- *LAML = adult AML data available on TCGA (The Cancer Genome Atlas) database accessed from *Gepia*
- 872 ** The expression of LONP1 showed reverse expression trend in validation cohort when compared to RNA
- 873 sequencing data of test cohort hence considered not validated.

874

875

877 Table 4: List of genes showing significant correlation with mitochondrial DNA copy number

878 using Pearson's correlation

Gene name	Mitochondrial DNA Copy number (n=143)			
	Correlation coefficient (r)	p value		
ATP5J	0.133	0.024		
FASTKD1	0.158	0.008		
CLIC1	0.165	0.005		
RACK1/GNB2L1	0.174	0.003		
SDHC	0.172	0.004		
SLC25A3	0.155	0.009		

879 n= number of patients

880

881

Table 5: Impact of expression of individual genes and overall risk score on overall survival and event free survival of the test cohort (pediatric cohort) and overall survival in validation cohort (TCGA adult LAML cohort)

Gene	Overall surv (Pediatric co n=143	vival hort)	Overall survival (T LAML coho n=179	CGA adult ort)	Event Free Survival (Pediatric cohort) n=143		
Name	Hazard Ratio (95% CI) P value		Hazard Ratio (95% CI)	P value	Hazard Ratio (95% CI)	P value	
SDHC	1.29(1.14-1.41)	< 0.001	0.994(0.941-1.050)	0.826	1.225(1.100-1.363)	< 0.001	
SLC25A29	0.88(0.83-0.93)	< 0.001	0.988(0.981-0.996)	0.003	0.905(0.860-0.952)	< 0.001	
CLIC1	1.20(1.04-1.38)	0.013	1.002(1.00-1.004)	0.069	1.136(0.984-1.312)	0.082	
Risk Score	1.010(1.007-1.014)	<0.001	1.011(1.002-1.021)	0.019	1.008(1.001-1.012)	< 0.001	

CI: Confidence interval; n= number of patients; TCGA The cancer genome atlas; LAML Adult AML dataset

Variables (n=143)	Categories (n)	Univariable analysis			Multivariable analysis		
		Median	Hazard (95% CI)	p value	Hazard (95% CI)	p value	
Age(years)	≤10 (64)	20.63	0.98(0.63-1.52)	0.93	_	-	
	>10(79)	21.93					
Gender	Male (87)	15.07	0.72(0.45-1.143)	0.16	-	-	
	Female (56)	40.23					
Total leukocyte	<50000(98)	23.77	0.8(0.517-1.238)	0.32	-	-	
count (/mm ³)	>50000(45)	13.88	-				
Platelets (/µL)	≤ 50000(92)	19.53	0.94(0.59-1.48)	0.789	-	-	
	>50000(51)	23.33					
Haemoglobin(g/dl)	≤8(95)	13.87	0.73(0.47-1.12)	0.16	-	-	
	>8(48)	24.87	_				
Fever	Negative (26)	Not reached	1.52(0.82-2.83) 0.18		-	-	
	Positive (112)	19.53					
Chloroma (n=132)	Negative (105)	20.63	0.56(0.29-1.07) 0.0	0.083	1.45(0.74-2.84)	0.27	
	Positive (27)	Not reached	_				
ELN Risk group	Good (67)	40.23	1.95(1.23-3.09)	0.004	0.59(0.36-0.98)	0.041	
(n=134)	Others (67)	12.27					

903 Table 6: Univariable and multivariable analysis of clinical features with overall survival

904 CI: Confidence interval; ELN: European LeukemiaNet.

905

906

907

Characteristics (n=143)	Risk score Low (%) (n=71)	Risk score High (%) (n=72)	χ^2	P value
Age (years)	(()		
<10 Years (64)	26(36.6)	38(52.8)		0.052
≥10 years (79)	45(63.4)	34(47.2)	3.775	
Sex	I		I	1
Male (87)	42(59.2)	45(62.5)	0.4.40	
Female (56)	29(40.8)	27(37.5)	0.168	0.682
Hyperleukocytosis, (>50×10 ³ /µL)				1
TLC <50×10 ³ /µL (98)	53(74.6)	45(62.5)		
TLC≥50×10 ³ /µL (45)	18(25.4)	27(37.5)	2.446	0.118
Fever(n=138)	1			
Negative (26)	17(24.6)	9(13.0)		0.082
Positive (112)	52(75.4)	60(87.0)	3.033	
Chloroma	I		I	1
Negative (116)	57(80.3)	59(81.9)	1 501	0.182
Positive (27)	14(19.7)	13(18.1)	1.781	
Cytogenetics (n=130) *	I		I	1
Good Risk (50)	32(54.2)	18(32.7)		0.001
Others (64)	27(45.8)	37(67.3)	5.349	0.021
Molecular analysis (n= 122) **	I		I	1
FLT3ITD				
Negative (105)	54(87.1)	51(85.0)		
Positive (17)	8(12.9)	9(15.0)	0.112	0.738
RUNX1-RUNX1T1	I		I	1
Negative (69)	29(46.8)	40(66.7)	4.011	0.007
Positive (53)	33(53.2)	20(33.3)	4.911	0.027
CBFB-MYH11 #	I		I	1
Negative (113)	58(93.5)	55(91.7)		1.00##
Positive (6)	3(4.83)	3(5.0)	_	1.00""
NPM1				-
Negative (117)	61(98.4)	56(93.3)		0.203##
Positive (5)	1(1.61)	4(6.7)	-	

909 Table 7: Association of 3-gene risk score with clinical and demographic parameters

ELN Risk stratification (n=134) ***							
Good Risk (67)	41(60.3)	26(39.4)	5.050	0.016			
Intermediate and poor risk (67)	27(39.7)	40(60.6)	- 5.852				
Complete remission (n=143)							
Achieved (104)	58(81.7)	46(63.9)	5 711	0.017			
Not achieved (39)	13(18.3)	26(36.1)	5./11	0.017			

910 *Cytogenetics failed (n=16) and not done in n=13 cases.

911 ** Molecular analysis was not done in 19 cases; molecular mutation was absent in n=43 cases

912 #CBFB-MYH11 mutation was assessed in n=119 cases

913 ^{##}Fisher's Exact Test

914 ***ELN (European LeukemiaNet) risk stratification was done using both cytogenetics and molecular markers in

915 134 patients. However, 12 patients risk stratification was done with only cytogenetics and in 20 patients, it was916 done by only molecular analysis

917 χ 2: Chi square value; TLC: Total leukocyte count; *FLT3 ITD*: FMS-like tyrosine kinase internal

918 tandem duplication; *RUNX1-RUNX1T1*: runt-related transcription factor 1-RUNX1 partner transcriptional co-919 repressor 1 fusion transcript; *CBFB-MYH11*: core binding factor beta-myosin heavy chain 11 fusion transcript;

920 *NPM1*: Nucleophosmin 1;

921

923 Table 8: Predictive ability of combined gene risk score group and ELN risk category on

924 survival outcome in pediatric AML cohort

	Variables(n)	HR (95%CI)	P Value	P value (overall)	Median OS (months)	Predicted 12 months survival	Predicted18 months survival
	ELN Good risk & gene signature risk group Low (41)	1		<0.001	Not reached	80%±6%	75%±7%
	ELN Others & gene signature risk group Low (27)	1.58 (0.78- 3.21)	0.20	-	27.77(±7.82)	74% ±8%	58% ±10%
	ELN Good risk & gene signature risk group High (26)	2.12 (1.06- 4.26)	0.034	-	22.90(±8.31)	54% ±10%	44% ±10%
	ELN Others & gene signature risk group High (40)	3.83 (2.07- 7.07)	< 0.001	-	4.67(±3.71)	33% ± 8%	25% ± 7%
926 927	HR: Hazard Ratio; CI: Con myeloid leukemia	nfidence interval;	; OS: over	all survival;	ELN: European	LeukemiaNet	; AML: Acute
928							
929							
930							
931							
932							
933							
934							
935							
936							
937							
938							
939							